The
p14(ARF)
protein directly inhibits the MDM-2
oncoprotein, which mediates degradation of the p53
protein. It has been shown that
p14(ARF) expression is frequently down-regulated by
p14(ARF) gene hypermethylation in
colorectal cancer. To determine whether
p14(ARF) inactivation was involved in
ulcerative colitis (UC)-associated
carcinogenesis, the frequency and timing of
p14(ARF) methylation was investigated in four different histological stages of UC-associated
carcinogenesis. Methylation-specific PCR and
bisulfite sequencing were used to determine the prevalence of
p14(ARF) gene methylation.
p14(ARF) methylation was observed in 19 of 38 (50%)
adenocarcinomas, 4 of 12 (33%) dysplasias, and 3 of the 5 (60%) nonneoplastic UC mucosae. In contrast, 3 of 40 (3.7%) normal tissues showed
p14(ARF) methylation (chi(2) test: P = 0.0003).
Bisulfite sequencing was used to analyze 28 CpGs of
p14(ARF) gene in 20 samples. The number of methylated CpGs ranged from 0 to 4, 0 to 20, and 0 to 28 in the normal, dysplastic, and carcinomatous samples, respectively (Kruskall-Wallis test: P = 0.0005). Densely methylated alleles were detected only in
carcinomas by
bisulfite sequencing. In conclusion, our data suggest that methylation of
p14(ARF) is a relatively common early event in UC-associated
carcinogenesis.
p14(ARF) offers potential as a
biomarker for the early detection of
cancer or dysplasia in UC. Finally, analyses of
p14(ARF) methylation in other organs should explore not only frank
cancers but other premalignant lesions.